View Future GrowthArcoma 過去の業績過去 基準チェック /26Arcomaは、平均年間58%の収益成長を遂げていますが、 Medical Equipment業界の収益は、年間 成長しています。収益は、平均年間19.3% 5%収益成長率で 成長しています。 Arcomaの自己資本利益率は5%であり、純利益率は3%です。主要情報58.04%収益成長率57.71%EPS成長率Medical Equipment 業界の成長6.16%収益成長率5.02%株主資本利益率5.03%ネット・マージン2.99%次回の業績アップデート20 Aug 2026最近の業績更新Reported Earnings • Apr 26First quarter 2026 earnings released: EPS: kr0.057 (vs kr0.15 in 1Q 2025)First quarter 2026 results: EPS: kr0.057 (down from kr0.15 in 1Q 2025). Revenue: kr31.9m (down 8.4% from 1Q 2025). Net income: kr811.0k (down 60% from 1Q 2025). Profit margin: 2.5% (down from 5.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Apr 10+ 2 more updatesArcoma AB to Report Q1, 2026 Results on Apr 23, 2026Arcoma AB announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Feb 13Arcoma AB to Report Fiscal Year 2025 Results on Apr 09, 2026Arcoma AB announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: kr0 (vs kr0.28 in 2Q 2024)Second quarter 2025 results: EPS: kr0 (down from kr0.28 in 2Q 2024). Revenue: kr31.5m (down 24% from 2Q 2024). Net income: kr4.0k (down 100% from 2Q 2024). Profit margin: 0% (down from 8.8% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 05First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: kr0.15 (down from kr0.34 in 1Q 2024). Revenue: kr35.8m (down 23% from 1Q 2024). Net income: kr2.04m (down 55% from 1Q 2024). Profit margin: 5.7% (down from 9.7% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 15Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: kr0.85 (up from kr0.19 in FY 2023). Revenue: kr160.5m (down 1.6% from FY 2023). Net income: kr11.2m (up 336% from FY 2023). Profit margin: 7.0% (up from 1.6% in FY 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 9.9%. Earnings per share (EPS) also missed analyst estimates by 28%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr8.58, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Medical Equipment industry in Sweden. Total returns to shareholders of 5.9% over the past three years.Price Target Changed • Apr 26Price target decreased by 16% to kr9.50Down from kr11.25, the current price target is provided by 1 analyst. New target price is 20% above last closing price of kr7.94. Stock is down 11% over the past year. The company is forecast to post earnings per share of kr0.55 for next year compared to kr0.35 last year.Reported Earnings • Apr 26First quarter 2026 earnings released: EPS: kr0.057 (vs kr0.15 in 1Q 2025)First quarter 2026 results: EPS: kr0.057 (down from kr0.15 in 1Q 2025). Revenue: kr31.9m (down 8.4% from 1Q 2025). Net income: kr811.0k (down 60% from 1Q 2025). Profit margin: 2.5% (down from 5.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (kr109.0m market cap, or US$11.8m).お知らせ • Apr 13Arcoma AB, Annual General Meeting, May 20, 2026Arcoma AB, Annual General Meeting, May 20, 2026, at 13:00 W. Europe Standard Time. Location: at the company`s premises, at annavagen 1, vaxjo Swedenお知らせ • Apr 10+ 2 more updatesArcoma AB to Report Q1, 2026 Results on Apr 23, 2026Arcoma AB announced that they will report Q1, 2026 results on Apr 23, 2026New Risk • Feb 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.8% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (kr111.9m market cap, or US$12.5m).Major Estimate Revision • Feb 13Consensus EPS estimates fall by 24%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr134.0m to kr131.0m. EPS estimate also fell from kr0.46 per share to kr0.35 per share. Net income forecast to grow 31% next year vs 38% growth forecast for Medical Equipment industry in Sweden. Consensus price target down from kr11.25 to kr10.75. Share price rose 2.6% to kr7.80 over the past week.お知らせ • Feb 13Arcoma AB to Report Fiscal Year 2025 Results on Apr 09, 2026Arcoma AB announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026分析記事 • Oct 30Investors Aren't Entirely Convinced By Arcoma AB's (STO:ARCOMA) EarningsWith a price-to-earnings (or "P/E") ratio of 18.8x Arcoma AB ( STO:ARCOMA ) may be sending bullish signals at the...New Risk • Oct 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.4% Last year net profit margin: 6.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (4.4% net profit margin). Market cap is less than US$100m (kr128.2m market cap, or US$13.7m).Major Estimate Revision • Oct 14Consensus EPS estimates fall by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr145.0m to kr140.0m. EPS estimate also fell from kr0.65 per share to kr0.54 per share. Net income forecast to grow 36% next year vs 40% growth forecast for Medical Equipment industry in Sweden. Consensus price target of kr11.50 unchanged from last update. Share price rose 4.5% to kr9.28 over the past week.分析記事 • Aug 24Arcoma AB (STO:ARCOMA) Analysts Are Cutting Their Estimates: Here's What You Need To KnowLast week, you might have seen that Arcoma AB ( STO:ARCOMA ) released its second-quarter result to the market. The...Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: kr0 (vs kr0.28 in 2Q 2024)Second quarter 2025 results: EPS: kr0 (down from kr0.28 in 2Q 2024). Revenue: kr31.5m (down 24% from 2Q 2024). Net income: kr4.0k (down 100% from 2Q 2024). Profit margin: 0% (down from 8.8% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Jul 09Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr162.0m to kr153.0m. EPS estimate also fell from kr0.85 per share to kr0.73 per share. Net income forecast to grow 9.0% next year vs 38% growth forecast for Medical Equipment industry in Sweden. Consensus price target of kr12.50 unchanged from last update. Share price rose 3.6% to kr9.90 over the past week.分析記事 • Jul 09Arcoma AB (STO:ARCOMA) Looks Inexpensive But Perhaps Not Attractive EnoughArcoma AB's ( STO:ARCOMA ) price-to-earnings (or "P/E") ratio of 16x might make it look like a buy right now compared...Price Target Changed • May 19Price target decreased by 18% to kr12.50Down from kr15.25, the current price target is provided by 1 analyst. New target price is 29% above last closing price of kr9.70. Stock is down 34% over the past year. The company is forecast to post earnings per share of kr0.85 for next year compared to kr0.85 last year.Reported Earnings • May 05First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: kr0.15 (down from kr0.34 in 1Q 2024). Revenue: kr35.8m (down 23% from 1Q 2024). Net income: kr2.04m (down 55% from 1Q 2024). Profit margin: 5.7% (down from 9.7% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 04Arcoma AB, Annual General Meeting, May 14, 2025Arcoma AB, Annual General Meeting, May 14, 2025, at 13:00 W. Europe Standard Time. Location: at the companys premises, at annavagen 1, vaxjo SwedenReported Earnings • Feb 15Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: kr0.85 (up from kr0.19 in FY 2023). Revenue: kr160.5m (down 1.6% from FY 2023). Net income: kr11.2m (up 336% from FY 2023). Profit margin: 7.0% (up from 1.6% in FY 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 9.9%. Earnings per share (EPS) also missed analyst estimates by 28%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.分析記事 • Nov 09Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price DropArcoma AB ( STO:ARCOMA ) shareholders that were waiting for something to happen have been dealt a blow with a 28% share...Price Target Changed • Oct 25Price target increased by 13% to kr17.00Up from kr15.00, the current price target is provided by 1 analyst. New target price is 35% above last closing price of kr12.55. Stock is up 64% over the past year. The company is forecast to post earnings per share of kr1.10 for next year compared to kr0.19 last year.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to kr12.55, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 6x in the Medical Equipment industry in Sweden. Total loss to shareholders of 9.7% over the past three years.分析記事 • Aug 22Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A BusinessArcoma AB's ( STO:ARCOMA ) earnings announcement last week was disappointing for investors, despite the decent profit...Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: kr0.28 (vs kr0.031 in 2Q 2023)Second quarter 2024 results: EPS: kr0.28 (up from kr0.031 in 2Q 2023). Revenue: kr42.5m (up 11% from 2Q 2023). Net income: kr3.66m (up kr3.25m from 2Q 2023). Profit margin: 8.6% (up from 1.1% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.分析記事 • Aug 07At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it saw a double-digit share price rise of over 10...Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: kr0.34 (vs kr0.18 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.34 (up from kr0.18 loss in 1Q 2023). Revenue: kr47.4m (up 26% from 1Q 2023). Net income: kr4.50m (up kr6.84m from 1Q 2023). Profit margin: 9.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.分析記事 • Apr 26Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it saw a significant share price rise of 68% in the...お知らせ • Mar 15+ 4 more updatesArcoma AB to Report Q1, 2024 Results on Apr 25, 2024Arcoma AB announced that they will report Q1, 2024 results on Apr 25, 2024Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr10.90, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 13x in the Medical Equipment industry in Sweden. Total loss to shareholders of 56% over the past three years.分析記事 • Feb 06Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price BounceThe Arcoma AB ( STO:ARCOMA ) share price has done very well over the last month, posting an excellent gain of 25...Reported Earnings • Jan 31Full year 2023 earnings: EPS in line with analyst expectations despite revenue beatFull year 2023 results: EPS: kr0.19 (up from kr0.15 in FY 2022). Revenue: kr166.0m (up 33% from FY 2022). Net income: kr2.56m (up 35% from FY 2022). Profit margin: 1.5% (in line with FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.New Risk • Jan 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr103.5m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.分析記事 • Jan 15Is Arcoma (STO:ARCOMA) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr0.15 (vs kr0.11 in 3Q 2022)Third quarter 2023 results: EPS: kr0.15 (up from kr0.11 in 3Q 2022). Revenue: kr36.5m (up 26% from 3Q 2022). Net income: kr1.98m (up 36% from 3Q 2022). Profit margin: 5.4% (up from 5.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 25% per year.分析記事 • Sep 11We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Aug 18Second quarter 2023 earnings released: EPS: kr0.031 (vs kr0.11 in 2Q 2022)Second quarter 2023 results: EPS: kr0.031 (down from kr0.11 in 2Q 2022). Revenue: kr39.2m (up 27% from 2Q 2022). Net income: kr404.0k (down 71% from 2Q 2022). Profit margin: 1.0% (down from 4.6% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.分析記事 • Jun 08Is Arcoma (STO:ARCOMA) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 01First quarter 2023 earnings released: kr0.18 loss per share (vs kr0.093 loss in 1Q 2022)First quarter 2023 results: kr0.18 loss per share (further deteriorated from kr0.093 loss in 1Q 2022). Revenue: kr37.9m (up 56% from 1Q 2022). Net loss: kr2.34m (loss widened 93% from 1Q 2022). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.分析記事 • Apr 27Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it led the OM gainers with a relatively large price...Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr0.14 (vs kr0.58 loss in FY 2021)Full year 2022 results: EPS: kr0.14 (up from kr0.58 loss in FY 2021). Revenue: kr129.9m (up 11% from FY 2021). Net income: kr1.90m (up kr9.38m from FY 2021). Profit margin: 1.5% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.分析記事 • Dec 22Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jan Wahlstrom was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: kr0.11 (vs kr0.24 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.11 (up from kr0.24 loss in 3Q 2021). Revenue: kr30.4m (up 31% from 3Q 2021). Net income: kr1.45m (up kr4.54m from 3Q 2021). Profit margin: 4.8% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 19Second quarter 2022 earnings released: EPS: kr0.11 (vs kr0.079 in 2Q 2021)Second quarter 2022 results: EPS: kr0.11 (up from kr0.079 in 2Q 2021). Revenue: kr33.2m (down 7.6% from 2Q 2021). Net income: kr1.41m (up 37% from 2Q 2021). Profit margin: 4.2% (up from 2.9% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 40%, compared to a 98% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.Reported Earnings • May 03First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: kr0.093 loss per share (down from kr0.15 profit in 1Q 2021). Revenue: kr24.4m (down 34% from 1Q 2021). Net loss: kr1.21m (down 165% from profit in 1Q 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 30%, compared to a 99% growth forecast for the industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.分析記事 • May 03Is Arcoma (STO:ARCOMA) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Price Target Changed • Apr 27Price target decreased to kr16.50Down from kr25.00, the current price target is provided by 1 analyst. New target price is 74% above last closing price of kr9.50. Stock is down 55% over the past year. The company is forecast to post earnings per share of kr0.24 next year compared to a net loss per share of kr0.58 last year.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Jesper Söderqvist was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Feb 15Director recently bought kr119k worth of stockOn the 10th of February, Mats Thoren bought around 10k shares on-market at roughly kr11.94 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Feb 11Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: kr0.57 loss per share (down from kr0.11 profit in FY 2020). Revenue: kr118.0m (flat on FY 2020). Net loss: kr7.47m (down kr8.84m from profit in FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 43%, compared to a 136% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Price Target Changed • Oct 31Price target decreased to kr21.00Down from kr25.00, the current price target is provided by 1 analyst. New target price is 52% above last closing price of kr13.80. Stock is down 22% over the past year. The company is forecast to post earnings per share of kr0.14 for next year compared to kr0.11 last year.Reported Earnings • Oct 30Third quarter 2021 earnings released: kr0.24 loss per share (vs kr0.082 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr23.2m (up 4.2% from 3Q 2020). Net loss: kr3.09m (down 394% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.分析記事 • Oct 28These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt ExtensivelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Aug 27Second quarter 2021 earnings released: EPS kr0.079 (vs kr0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr36.0m (up 14% from 2Q 2020). Net income: kr1.03m (down 55% from 2Q 2020). Profit margin: 2.9% (down from 7.3% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 27First quarter 2021 earnings released: EPS kr0.15 (vs kr0.31 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: kr36.9m (up 11% from 1Q 2020). Net income: kr1.87m (down 53% from 1Q 2020). Profit margin: 5.1% (down from 12% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 17Is Arcoma (STO:ARCOMA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyst Estimate Surprise Post Earnings • Feb 20Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.9%. Earnings per share (EPS) also missed analyst estimates by 84%. Over the next year, revenue is forecast to grow 35%, compared to a 439% growth forecast for the Medical Equipment industry in Sweden.Reported Earnings • Feb 20Full year 2020 earnings released: EPS kr0.12 (vs kr0.52 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr117.4m (down 12% from FY 2019). Net income: kr1.44m (down 78% from FY 2019). Profit margin: 1.2% (down from 4.9% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 18Arcoma AB, Annual General Meeting, May 25, 2021Arcoma AB, Annual General Meeting, May 25, 2021.分析記事 • Feb 04Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?While Arcoma AB ( STO:ARCOMA ) might not be the most widely known stock at the moment, it received a lot of attention...分析記事 • Jan 14Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?We note that a Arcoma AB ( STO:ARCOMA ) insider, Johan Henningsson, recently sold kr390k worth of stock for kr25.18 per...Recent Insider Transactions • Jan 14Insider recently sold kr390k worth of stockOn the 8th of January, Johan Henningsson sold around 15k shares on-market at roughly kr25.18 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.分析記事 • Jan 12Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Arcoma (STO:ARCOMA) has had a great run on the share market with its stock up by a significant 31% over the last three...Valuation Update With 7 Day Price Move • Jan 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr25.60, the stock is trading at a trailing P/E ratio of 40.1x, up from the previous P/E ratio of 34.5x. This compares to an average P/E of 34x in the Medical Equipment industry in Sweden. Total returns to shareholders over the past three years are 234%.Is New 90 Day High Low • Dec 28New 90-day high: kr21.90The company is up 13% from its price of kr19.30 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.分析記事 • Dec 17These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Dec 01Arcoma AB Launches Omnera 500AArcoma AB launches the new X-ray system Omnera 500A on the American market. OMNERA 500A Includes New Intelligent Automation Features to Help Improve Workflow and Efficiency, Without Compromising on Patient Care. The OMNERA 500A offers outstanding performance and intelligent automation with features that puts efficiency and patient safety first. The system has a new design and a new modern user interface with smart functions that simplify workflow and are designed to facilitate disinfection. The OMNERA 500A also has a completely new wall stand and an updated X-ray table that improves the patient and user experience.分析記事 • Nov 21Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)Does the November share price for Arcoma AB (STO:ARCOMA) reflect what it's really worth? Today, we will estimate the...Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS kr0.082The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: kr22.2m (down 27% from 3Q 2019). Net income: kr1.05m (down 61% from 3Q 2019). Profit margin: 4.7% (down from 8.8% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Nov 13Analysts update estimatesThe 2020 consensus earning per share (EPS) estimate increased from kr0.60 to kr0.67. No change was made to the revenue estimate which at the last update was kr124.0m. Net income is expected to shrink by 7.7% next year compared to 29% growth forecast for the Medical Equipment industry in Sweden . The consensus price target was lowered from kr27.00 to kr25.00. Share price is down by 6.8% to kr17.25 over the past week.Price Target Changed • Nov 13Price target lowered to kr25.00Down from kr27.00, the current price target is provided by 1 analyst. The new target price is 45% above the current share price of kr17.25. As of last close, the stock is down 26% over the past year.Is New 90 Day High Low • Nov 12New 90-day low: kr17.00The company is down 5.0% from its price of kr17.95 on 14 August 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period.Is New 90 Day High Low • Oct 15New 90-day low: kr17.50The company is down 8.0% from its price of kr18.95 on 17 July 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period.収支内訳Arcoma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OM:ARCOMA 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 26127439031 Dec 25131539030 Sep 25133639030 Jun 25135739031 Mar 251451041031 Dec 241571143030 Sep 241711144030 Jun 241751145031 Mar 24172845031 Dec 23163345030 Sep 23153046030 Jun 23146045031 Mar 23138144031 Dec 22125243030 Sep 22105-644030 Jun 2299-1044031 Mar 22105-1144031 Dec 21117-745030 Sep 21126-645030 Jun 21125-244031 Mar 21121-141031 Dec 20117138030 Sep 20122834030 Jun 201301036031 Mar 201321038031 Dec 19134739030 Sep 19133540030 Jun 19132240031 Mar 19129141031 Dec 18119-242030 Sep 18111-142030 Jun 1898-642031 Mar 1894-1041031 Dec 1792-1040030 Sep 1798-941030 Jun 17108-442031 Mar 17106-545031 Dec 16102-1247030 Sep 16106-1249030 Jun 16105-1348031 Mar 16104-1548031 Dec 15123-649030 Sep 15117-647030 Jun 15119-5460質の高い収益: ARCOMAは 高品質の収益 を持っています。利益率の向上: ARCOMAの現在の純利益率 (3%)は、昨年(6.6%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ARCOMA過去 5 年間で収益を上げており、収益は年間58%増加しています。成長の加速: ARCOMAは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: ARCOMAは過去 1 年間で収益成長率がマイナス ( -60.6% ) となったため、 Medical Equipment業界平均 ( -17.5% ) と比較することが困難です。株主資本利益率高いROE: ARCOMAの 自己資本利益率 ( 5% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 22:28終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Arcoma AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Hjalmar JernstromDNB Carnegie Commissioned Research
Reported Earnings • Apr 26First quarter 2026 earnings released: EPS: kr0.057 (vs kr0.15 in 1Q 2025)First quarter 2026 results: EPS: kr0.057 (down from kr0.15 in 1Q 2025). Revenue: kr31.9m (down 8.4% from 1Q 2025). Net income: kr811.0k (down 60% from 1Q 2025). Profit margin: 2.5% (down from 5.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Apr 10+ 2 more updatesArcoma AB to Report Q1, 2026 Results on Apr 23, 2026Arcoma AB announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Feb 13Arcoma AB to Report Fiscal Year 2025 Results on Apr 09, 2026Arcoma AB announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026
Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: kr0 (vs kr0.28 in 2Q 2024)Second quarter 2025 results: EPS: kr0 (down from kr0.28 in 2Q 2024). Revenue: kr31.5m (down 24% from 2Q 2024). Net income: kr4.0k (down 100% from 2Q 2024). Profit margin: 0% (down from 8.8% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 05First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: kr0.15 (down from kr0.34 in 1Q 2024). Revenue: kr35.8m (down 23% from 1Q 2024). Net income: kr2.04m (down 55% from 1Q 2024). Profit margin: 5.7% (down from 9.7% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 15Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: kr0.85 (up from kr0.19 in FY 2023). Revenue: kr160.5m (down 1.6% from FY 2023). Net income: kr11.2m (up 336% from FY 2023). Profit margin: 7.0% (up from 1.6% in FY 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 9.9%. Earnings per share (EPS) also missed analyst estimates by 28%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr8.58, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Medical Equipment industry in Sweden. Total returns to shareholders of 5.9% over the past three years.
Price Target Changed • Apr 26Price target decreased by 16% to kr9.50Down from kr11.25, the current price target is provided by 1 analyst. New target price is 20% above last closing price of kr7.94. Stock is down 11% over the past year. The company is forecast to post earnings per share of kr0.55 for next year compared to kr0.35 last year.
Reported Earnings • Apr 26First quarter 2026 earnings released: EPS: kr0.057 (vs kr0.15 in 1Q 2025)First quarter 2026 results: EPS: kr0.057 (down from kr0.15 in 1Q 2025). Revenue: kr31.9m (down 8.4% from 1Q 2025). Net income: kr811.0k (down 60% from 1Q 2025). Profit margin: 2.5% (down from 5.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (kr109.0m market cap, or US$11.8m).
お知らせ • Apr 13Arcoma AB, Annual General Meeting, May 20, 2026Arcoma AB, Annual General Meeting, May 20, 2026, at 13:00 W. Europe Standard Time. Location: at the company`s premises, at annavagen 1, vaxjo Sweden
お知らせ • Apr 10+ 2 more updatesArcoma AB to Report Q1, 2026 Results on Apr 23, 2026Arcoma AB announced that they will report Q1, 2026 results on Apr 23, 2026
New Risk • Feb 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.8% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (kr111.9m market cap, or US$12.5m).
Major Estimate Revision • Feb 13Consensus EPS estimates fall by 24%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr134.0m to kr131.0m. EPS estimate also fell from kr0.46 per share to kr0.35 per share. Net income forecast to grow 31% next year vs 38% growth forecast for Medical Equipment industry in Sweden. Consensus price target down from kr11.25 to kr10.75. Share price rose 2.6% to kr7.80 over the past week.
お知らせ • Feb 13Arcoma AB to Report Fiscal Year 2025 Results on Apr 09, 2026Arcoma AB announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026
分析記事 • Oct 30Investors Aren't Entirely Convinced By Arcoma AB's (STO:ARCOMA) EarningsWith a price-to-earnings (or "P/E") ratio of 18.8x Arcoma AB ( STO:ARCOMA ) may be sending bullish signals at the...
New Risk • Oct 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.4% Last year net profit margin: 6.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (4.4% net profit margin). Market cap is less than US$100m (kr128.2m market cap, or US$13.7m).
Major Estimate Revision • Oct 14Consensus EPS estimates fall by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr145.0m to kr140.0m. EPS estimate also fell from kr0.65 per share to kr0.54 per share. Net income forecast to grow 36% next year vs 40% growth forecast for Medical Equipment industry in Sweden. Consensus price target of kr11.50 unchanged from last update. Share price rose 4.5% to kr9.28 over the past week.
分析記事 • Aug 24Arcoma AB (STO:ARCOMA) Analysts Are Cutting Their Estimates: Here's What You Need To KnowLast week, you might have seen that Arcoma AB ( STO:ARCOMA ) released its second-quarter result to the market. The...
Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: kr0 (vs kr0.28 in 2Q 2024)Second quarter 2025 results: EPS: kr0 (down from kr0.28 in 2Q 2024). Revenue: kr31.5m (down 24% from 2Q 2024). Net income: kr4.0k (down 100% from 2Q 2024). Profit margin: 0% (down from 8.8% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Jul 09Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr162.0m to kr153.0m. EPS estimate also fell from kr0.85 per share to kr0.73 per share. Net income forecast to grow 9.0% next year vs 38% growth forecast for Medical Equipment industry in Sweden. Consensus price target of kr12.50 unchanged from last update. Share price rose 3.6% to kr9.90 over the past week.
分析記事 • Jul 09Arcoma AB (STO:ARCOMA) Looks Inexpensive But Perhaps Not Attractive EnoughArcoma AB's ( STO:ARCOMA ) price-to-earnings (or "P/E") ratio of 16x might make it look like a buy right now compared...
Price Target Changed • May 19Price target decreased by 18% to kr12.50Down from kr15.25, the current price target is provided by 1 analyst. New target price is 29% above last closing price of kr9.70. Stock is down 34% over the past year. The company is forecast to post earnings per share of kr0.85 for next year compared to kr0.85 last year.
Reported Earnings • May 05First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: kr0.15 (down from kr0.34 in 1Q 2024). Revenue: kr35.8m (down 23% from 1Q 2024). Net income: kr2.04m (down 55% from 1Q 2024). Profit margin: 5.7% (down from 9.7% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 04Arcoma AB, Annual General Meeting, May 14, 2025Arcoma AB, Annual General Meeting, May 14, 2025, at 13:00 W. Europe Standard Time. Location: at the companys premises, at annavagen 1, vaxjo Sweden
Reported Earnings • Feb 15Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: kr0.85 (up from kr0.19 in FY 2023). Revenue: kr160.5m (down 1.6% from FY 2023). Net income: kr11.2m (up 336% from FY 2023). Profit margin: 7.0% (up from 1.6% in FY 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 9.9%. Earnings per share (EPS) also missed analyst estimates by 28%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
分析記事 • Nov 09Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price DropArcoma AB ( STO:ARCOMA ) shareholders that were waiting for something to happen have been dealt a blow with a 28% share...
Price Target Changed • Oct 25Price target increased by 13% to kr17.00Up from kr15.00, the current price target is provided by 1 analyst. New target price is 35% above last closing price of kr12.55. Stock is up 64% over the past year. The company is forecast to post earnings per share of kr1.10 for next year compared to kr0.19 last year.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to kr12.55, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 6x in the Medical Equipment industry in Sweden. Total loss to shareholders of 9.7% over the past three years.
分析記事 • Aug 22Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A BusinessArcoma AB's ( STO:ARCOMA ) earnings announcement last week was disappointing for investors, despite the decent profit...
Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: kr0.28 (vs kr0.031 in 2Q 2023)Second quarter 2024 results: EPS: kr0.28 (up from kr0.031 in 2Q 2023). Revenue: kr42.5m (up 11% from 2Q 2023). Net income: kr3.66m (up kr3.25m from 2Q 2023). Profit margin: 8.6% (up from 1.1% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
分析記事 • Aug 07At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it saw a double-digit share price rise of over 10...
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: kr0.34 (vs kr0.18 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.34 (up from kr0.18 loss in 1Q 2023). Revenue: kr47.4m (up 26% from 1Q 2023). Net income: kr4.50m (up kr6.84m from 1Q 2023). Profit margin: 9.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
分析記事 • Apr 26Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it saw a significant share price rise of 68% in the...
お知らせ • Mar 15+ 4 more updatesArcoma AB to Report Q1, 2024 Results on Apr 25, 2024Arcoma AB announced that they will report Q1, 2024 results on Apr 25, 2024
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr10.90, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 13x in the Medical Equipment industry in Sweden. Total loss to shareholders of 56% over the past three years.
分析記事 • Feb 06Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price BounceThe Arcoma AB ( STO:ARCOMA ) share price has done very well over the last month, posting an excellent gain of 25...
Reported Earnings • Jan 31Full year 2023 earnings: EPS in line with analyst expectations despite revenue beatFull year 2023 results: EPS: kr0.19 (up from kr0.15 in FY 2022). Revenue: kr166.0m (up 33% from FY 2022). Net income: kr2.56m (up 35% from FY 2022). Profit margin: 1.5% (in line with FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
New Risk • Jan 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr103.5m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
分析記事 • Jan 15Is Arcoma (STO:ARCOMA) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr0.15 (vs kr0.11 in 3Q 2022)Third quarter 2023 results: EPS: kr0.15 (up from kr0.11 in 3Q 2022). Revenue: kr36.5m (up 26% from 3Q 2022). Net income: kr1.98m (up 36% from 3Q 2022). Profit margin: 5.4% (up from 5.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 25% per year.
分析記事 • Sep 11We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Aug 18Second quarter 2023 earnings released: EPS: kr0.031 (vs kr0.11 in 2Q 2022)Second quarter 2023 results: EPS: kr0.031 (down from kr0.11 in 2Q 2022). Revenue: kr39.2m (up 27% from 2Q 2022). Net income: kr404.0k (down 71% from 2Q 2022). Profit margin: 1.0% (down from 4.6% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
分析記事 • Jun 08Is Arcoma (STO:ARCOMA) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 01First quarter 2023 earnings released: kr0.18 loss per share (vs kr0.093 loss in 1Q 2022)First quarter 2023 results: kr0.18 loss per share (further deteriorated from kr0.093 loss in 1Q 2022). Revenue: kr37.9m (up 56% from 1Q 2022). Net loss: kr2.34m (loss widened 93% from 1Q 2022). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
分析記事 • Apr 27Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?Arcoma AB ( STO:ARCOMA ), is not the largest company out there, but it led the OM gainers with a relatively large price...
Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr0.14 (vs kr0.58 loss in FY 2021)Full year 2022 results: EPS: kr0.14 (up from kr0.58 loss in FY 2021). Revenue: kr129.9m (up 11% from FY 2021). Net income: kr1.90m (up kr9.38m from FY 2021). Profit margin: 1.5% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
分析記事 • Dec 22Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jan Wahlstrom was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: kr0.11 (vs kr0.24 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.11 (up from kr0.24 loss in 3Q 2021). Revenue: kr30.4m (up 31% from 3Q 2021). Net income: kr1.45m (up kr4.54m from 3Q 2021). Profit margin: 4.8% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 19Second quarter 2022 earnings released: EPS: kr0.11 (vs kr0.079 in 2Q 2021)Second quarter 2022 results: EPS: kr0.11 (up from kr0.079 in 2Q 2021). Revenue: kr33.2m (down 7.6% from 2Q 2021). Net income: kr1.41m (up 37% from 2Q 2021). Profit margin: 4.2% (up from 2.9% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 40%, compared to a 98% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 03First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: kr0.093 loss per share (down from kr0.15 profit in 1Q 2021). Revenue: kr24.4m (down 34% from 1Q 2021). Net loss: kr1.21m (down 165% from profit in 1Q 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 30%, compared to a 99% growth forecast for the industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
分析記事 • May 03Is Arcoma (STO:ARCOMA) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Price Target Changed • Apr 27Price target decreased to kr16.50Down from kr25.00, the current price target is provided by 1 analyst. New target price is 74% above last closing price of kr9.50. Stock is down 55% over the past year. The company is forecast to post earnings per share of kr0.24 next year compared to a net loss per share of kr0.58 last year.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Jesper Söderqvist was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Feb 15Director recently bought kr119k worth of stockOn the 10th of February, Mats Thoren bought around 10k shares on-market at roughly kr11.94 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Feb 11Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: kr0.57 loss per share (down from kr0.11 profit in FY 2020). Revenue: kr118.0m (flat on FY 2020). Net loss: kr7.47m (down kr8.84m from profit in FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 43%, compared to a 136% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Price Target Changed • Oct 31Price target decreased to kr21.00Down from kr25.00, the current price target is provided by 1 analyst. New target price is 52% above last closing price of kr13.80. Stock is down 22% over the past year. The company is forecast to post earnings per share of kr0.14 for next year compared to kr0.11 last year.
Reported Earnings • Oct 30Third quarter 2021 earnings released: kr0.24 loss per share (vs kr0.082 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr23.2m (up 4.2% from 3Q 2020). Net loss: kr3.09m (down 394% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
分析記事 • Oct 28These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt ExtensivelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Aug 27Second quarter 2021 earnings released: EPS kr0.079 (vs kr0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr36.0m (up 14% from 2Q 2020). Net income: kr1.03m (down 55% from 2Q 2020). Profit margin: 2.9% (down from 7.3% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 27First quarter 2021 earnings released: EPS kr0.15 (vs kr0.31 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: kr36.9m (up 11% from 1Q 2020). Net income: kr1.87m (down 53% from 1Q 2020). Profit margin: 5.1% (down from 12% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 17Is Arcoma (STO:ARCOMA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyst Estimate Surprise Post Earnings • Feb 20Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.9%. Earnings per share (EPS) also missed analyst estimates by 84%. Over the next year, revenue is forecast to grow 35%, compared to a 439% growth forecast for the Medical Equipment industry in Sweden.
Reported Earnings • Feb 20Full year 2020 earnings released: EPS kr0.12 (vs kr0.52 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr117.4m (down 12% from FY 2019). Net income: kr1.44m (down 78% from FY 2019). Profit margin: 1.2% (down from 4.9% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 18Arcoma AB, Annual General Meeting, May 25, 2021Arcoma AB, Annual General Meeting, May 25, 2021.
分析記事 • Feb 04Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?While Arcoma AB ( STO:ARCOMA ) might not be the most widely known stock at the moment, it received a lot of attention...
分析記事 • Jan 14Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?We note that a Arcoma AB ( STO:ARCOMA ) insider, Johan Henningsson, recently sold kr390k worth of stock for kr25.18 per...
Recent Insider Transactions • Jan 14Insider recently sold kr390k worth of stockOn the 8th of January, Johan Henningsson sold around 15k shares on-market at roughly kr25.18 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
分析記事 • Jan 12Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Arcoma (STO:ARCOMA) has had a great run on the share market with its stock up by a significant 31% over the last three...
Valuation Update With 7 Day Price Move • Jan 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr25.60, the stock is trading at a trailing P/E ratio of 40.1x, up from the previous P/E ratio of 34.5x. This compares to an average P/E of 34x in the Medical Equipment industry in Sweden. Total returns to shareholders over the past three years are 234%.
Is New 90 Day High Low • Dec 28New 90-day high: kr21.90The company is up 13% from its price of kr19.30 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
分析記事 • Dec 17These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Dec 01Arcoma AB Launches Omnera 500AArcoma AB launches the new X-ray system Omnera 500A on the American market. OMNERA 500A Includes New Intelligent Automation Features to Help Improve Workflow and Efficiency, Without Compromising on Patient Care. The OMNERA 500A offers outstanding performance and intelligent automation with features that puts efficiency and patient safety first. The system has a new design and a new modern user interface with smart functions that simplify workflow and are designed to facilitate disinfection. The OMNERA 500A also has a completely new wall stand and an updated X-ray table that improves the patient and user experience.
分析記事 • Nov 21Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)Does the November share price for Arcoma AB (STO:ARCOMA) reflect what it's really worth? Today, we will estimate the...
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS kr0.082The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: kr22.2m (down 27% from 3Q 2019). Net income: kr1.05m (down 61% from 3Q 2019). Profit margin: 4.7% (down from 8.8% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Nov 13Analysts update estimatesThe 2020 consensus earning per share (EPS) estimate increased from kr0.60 to kr0.67. No change was made to the revenue estimate which at the last update was kr124.0m. Net income is expected to shrink by 7.7% next year compared to 29% growth forecast for the Medical Equipment industry in Sweden . The consensus price target was lowered from kr27.00 to kr25.00. Share price is down by 6.8% to kr17.25 over the past week.
Price Target Changed • Nov 13Price target lowered to kr25.00Down from kr27.00, the current price target is provided by 1 analyst. The new target price is 45% above the current share price of kr17.25. As of last close, the stock is down 26% over the past year.
Is New 90 Day High Low • Nov 12New 90-day low: kr17.00The company is down 5.0% from its price of kr17.95 on 14 August 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: kr17.50The company is down 8.0% from its price of kr18.95 on 17 July 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period.